Author:
Salzmann Martin,Leiter Ulrike,Loquai Carmen,Zimmer Lisa,Ugurel Selma,Gutzmer Ralf,Thoms Kai-Martin,Enk Alexander H.,Hassel Jessica C.
Funder
Abbvie
Bristol-Myers Squibb
Merck
Merck Sharp & Dohme
Novartis
Pfizer
MSD
Johnson & Johnson
Amgen
Merck Serono; has received
BMS
Roche
Pierre Fabre
Reference28 articles.
1. Incidence estimate of nonmelanoma skin cancer (Keratinocyte carcinomas) in the U.S. Population, 2012;Rogers;JAMA Dermatol,2015
2. Incidence, mortality, and trends of nonmelanoma skin cancer in Germany;Leiter;J Invest Dermatol,2017
3. Consensus for nonmelanoma skin cancer treatment, Part II: squamous cell carcinoma, including a cost analysis of treatment methods;Kauvar;Dermatol Surg : Off Publ Am Soc Dermatol Surg,2015
4. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?;Ribero;Curr Opin Oncol,2017
5. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG;Hillen;Eur J Canc (Oxford, England : 1990),2018
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献